Icon Genetics GmbH

ICON GENETICS is a provider of new plant engineering technologies which address precision, speed, yield, expression control and safety of transgene management in plants. We develop new generation production platforms and product prototypes for pharmaceutical, agricultural, animal health and chemical biotech markets. ICON GENETICS AG, Munich, Germany has been incorporated in 1999. The Company owns two subsidiaries: ICON GENETICS GmbH, Halle, and ICON GENETICS Inc., NJ, USA. Currently, we have 25 employees, operate research facilities in Halle (Saale), and Freising-Weihenstephan, and occupy over 1000 sq. m of space including over 300 sq. m of greenhouses. Additionally, there are 25 FTE and additional lab space under exclusive contracts with the International Institute of Cell Biology, Kiev, Ukraine and Lomonosov University, Moscow, Russia. So far, ICON GENETICS has generated over 280 FTE-years of research, filed 39 patent applications and exclusively in-licensed 2 patents covering all major platforms and elements and creating a strong 'exclusivity area' in new generation engineering. Several patent applications are in preparation. A number of optimized production processes and product prototypes have been developed that are superior to existing analogs. We successfully raised capital in two investment rounds generating more than $14 million in equity and long-term debt. Icon’s current investors include Sachsen LB, Leipzig, IBG, Magdeburg, and BioM, Munich. Over last 4 years, we raised more than $12 million in contracts, license fees and grants. Collaborations/contracts with Degussa, American Cyanamid, Large Scale Biology Corp., Sunol, Fermentas, Novoplant, Institute of Plant Genetics and Crop Plant Research, Gatersleben, and Ludwig-Maximilians-University, Munich. ICON GENETICS is managed by experienced directors and research managers with extensive knowledge of business and corporate research.